Evaluation of BrightGen HR RT-qDx assay to detect nuclear receptors mRNA overexpression in FFPE breast cancer tissue samples for selection of tamoxifen therapy.

PubWeight™: 0.75‹?›

🔗 View Article (PMC 4203191)

Published in Int J Clin Exp Pathol on August 15, 2014

Authors

Hye-Young Wang1, Sangjung Park2, Sunghyun Kim3, Sungwoo Ahn4, Dongsup Lee5, Seungil Kim6, Dongju Jung7, Kwang Hwa Park8, Hyeyoung Lee4

Author Affiliations

1: M&D, Inc., Wonju Eco Environmental Technology Center Gangwon, Republic of Korea.
2: Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University Wonju, Gangwon, Republic of Korea ; Department of Clinical Laboratory Science, College of Medical Science, Daegu Haany University Daegu, Republic of Korea.
3: Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University Wonju, Gangwon, Republic of Korea ; Institute for Life Science and Biotechnology, Yonsei University Seoul, Republic of Korea.
4: Department of Biomedical Laboratory Science, College of Health Sciences, Yonsei University Wonju, Gangwon, Republic of Korea.
5: Department of Clinical Laboratory Science, Hyejeon College Chungnam, Republic of Korea.
6: Department of Surgery, Yonsei University College of Medicine Seoul, Republic of Korea.
7: Department of Biomedical Laboratory Science, College of Natural Sciences, Hoseo University Chungnam, Republic of Korea.
8: Department of Pathology, Wonju College of Medicine, Yonsei University Gangwon, Republic of Korea.

Articles cited by this

Cancer statistics, 2005. CA Cancer J Clin (2005) 25.65

Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol (1999) 11.18

Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases. J Clin Oncol (2003) 3.58

RNA expression analysis of formalin-fixed paraffin-embedded tumors. Lab Invest (2007) 2.25

Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial. Breast Cancer Res Treat (2008) 1.82

Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol (2001) 1.76

Optimization of RNA extraction from FFPE tissues for expression profiling in the DASL assay. Biotechniques (2008) 1.72

Optimization of recovery of RNA from formalin-fixed, paraffin-embedded tissue. Diagn Mol Pathol (2006) 1.63

Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer. Cancer Treat Rev (2010) 1.62

Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance. J Clin Oncol (2008) 1.47

HER2 amplification status in breast cancer: a comparison between immunohistochemical staining and fluorescence in situ hybridisation using manual and automated quantitative image analysis scoring techniques. J Clin Pathol (2005) 1.45

Breast cancer (2). N Engl J Med (1992) 1.39

Quantitative PCR and HER2 testing in breast cancer: a technical and cost-effectiveness analysis. Am J Clin Pathol (2008) 1.12

Progress in endocrine approaches to the treatment and prevention of breast cancer. Maturitas (2011) 1.11

Nested-multiplex PCR detection of Orthopoxvirus and Parapoxvirus directly from exanthematic clinical samples. Virol J (2009) 1.10

The changing role of pathology in breast cancer diagnosis and treatment. Pathobiology (2011) 1.02

Validation of real-time RT-PCR for analysis of human breast cancer cell lines resistant or sensitive to treatment with antiestrogens. Endocr Relat Cancer (2003) 0.94

Progesterone regulation of stem and progenitor cells in normal and malignant breast. Mol Cell Endocrinol (2011) 0.93

Breast cancer patients with estrogen receptor-negative/progesterone receptor-positive tumors: being younger and getting less benefit from adjuvant tamoxifen treatment. J Cancer Res Clin Oncol (2008) 0.90

Immunohistochemical assessment of hormone receptor status using a new scoring system (J-Score) in breast cancer. Breast Cancer (2007) 0.86

Molecular morphological approach to the pathological study of development and advancement of human breast cancer. Med Mol Morphol (2010) 0.84